Drug intelligence / Profile preview

IMV-3

Development stage: Preclinical
Lead developer: ImmuVia
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

IMV-3 is a preclinical-stage bispecific antibody being developed by ImmuVia for the treatment of ovarian and endometrial cancers. It is engineered using the company's proprietary Cancerlysin™ platform. While the specific molecular targets for IMV-3 have not been publicly disclosed, the Cancerlysin™ platform is designed to create bispecific antibodies that engage tumor-associated antigens to induce therapeutic effects. The candidate is currently in the preclinical stage of development, focusing on gynecologic malignancies.

Targets

MUC16 (Mucin-16)TNFRSF10B (DR5)

Beyond the preview

Go deeper on IMV-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMV-3.

Explore the full profile